List of Excipients in Branded Drug PENTAZOCINE HYDROCHLORIDE AND ACETAMINOPHEN

Generic Drugs Containing PENTAZOCINE HYDROCHLORIDE AND ACETAMINOPHEN

Company	Ingredient	NDC	Excipient
GAVIS Pharmaceuticals LLC	pentazocine hydrochloride and acetaminophen	43386-670	CELLULOSE, MICROCRYSTALLINE
GAVIS Pharmaceuticals LLC	pentazocine hydrochloride and acetaminophen	43386-670	FD&C BLUE NO. 1
GAVIS Pharmaceuticals LLC	pentazocine hydrochloride and acetaminophen	43386-670	SILICON DIOXIDE
GAVIS Pharmaceuticals LLC	pentazocine hydrochloride and acetaminophen	43386-670	SODIUM LAURYL SULFATE
GAVIS Pharmaceuticals LLC	pentazocine hydrochloride and acetaminophen	43386-670	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in PENTAZOCINE HYDROCHLORIDE AND ACETAMINOPHEN?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C BLUE NO. 1
1	SILICON DIOXIDE
1	SODIUM LAURYL SULFATE
1	SODIUM STARCH GLYCOLATE TYPE A POTATO

Pentazocine Hydrochloride and Acetaminophen: Excipient Strategy, Patent Position, and Commercial Opportunity

Last updated: September 25, 2026

Pentazocine hydrochloride/acetaminophen is an off-patent oral analgesic combination with limited branded competition and a potentially narrow generic market. The reference product, Talacen, contains pentazocine hydrochloride 12.5 mg and acetaminophen 650 mg per tablet. The commercial opportunity is strongest for manufacturers that can deliver reliable content uniformity, low-cost tablet production, stable supply of controlled-substance active ingredient, and a differentiated packaging or abuse-risk profile.

The formulation is more commercially sensitive than its simple two-ingredient composition suggests. Pentazocine is a controlled opioid analgesic, while acetaminophen creates dose-related liver-safety constraints. A successful product must satisfy FDA combination-drug requirements, demonstrate bioequivalence to the reference product, comply with controlled-substance manufacturing rules, and maintain tight control of acetaminophen content and labeling.

What is pentazocine hydrochloride and acetaminophen?

Pentazocine hydrochloride/acetaminophen is an immediate-release oral tablet used for the relief of moderate to severe pain. Pentazocine is a synthetic opioid with mixed agonist-antagonist activity. Acetaminophen provides non-opioid analgesic activity and permits a lower opioid dose than pentazocine monotherapy. The labeled product strength is 12.5 mg of pentazocine hydrochloride and 650 mg of acetaminophen per tablet.[1]

Product attribute	Commercially relevant fact
Reference product	Talacen
Dosage form	Immediate-release tablet
Strength	Pentazocine hydrochloride 12.5 mg/acetaminophen 650 mg
Route	Oral
Therapeutic category	Prescription analgesic
Controlled-substance status	Pentazocine products are subject to U.S. controlled-substance requirements
Combination risk	Opioid-related dependence and acetaminophen-related hepatotoxicity
Primary generic route	Abbreviated New Drug Application, subject to FDA reference-product and bioequivalence requirements

The product is not a biologic and does not create a biosimilar pathway. The relevant competitive threats are authorized generics, ANDA products, repackagers, and potential 505(b)(2) products with materially different dosage forms or delivery systems.

What excipients are used in pentazocine hydrochloride and acetaminophen tablets?

The exact inactive-ingredient profile depends on the manufacturer and formulation. Immediate-release generic tablets typically use a compact excipient system built around a diluent, binder, disintegrant, glidant, and lubricant. FDA requires the inactive ingredients in an approved product to be disclosed in labeling or regulatory records.[1,2]

Core excipient functions

Formulation function	Candidate excipients	Strategic purpose
Dilution and compressibility	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Supports tablet weight, hardness, and content uniformity
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Controls breakup and immediate drug release
Flow control	Colloidal silicon dioxide	Improves powder flow and die filling
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Wetting or dissolution support	Sodium lauryl sulfate or selected surfactants	May improve wetting of poorly soluble components
Coating	Hypromellose, polyethylene glycol, titanium dioxide, permitted colorants	Supports swallowability, identification, and light protection

The primary development issue is not excipient novelty. It is the interaction between excipients, low-dose pentazocine, high-dose acetaminophen, and tablet manufacturing variability. Pentazocine represents a small fraction of total tablet mass. Segregation during blending can therefore create a content-uniformity risk even when the acetaminophen assay is within specification.

Which excipient strategy is most suitable?

A direct-compression formulation is the lowest-cost starting point if the active ingredients and selected excipient grades provide adequate flow and compactability. Direct compression reduces solvent use, processing time, and manufacturing complexity. It also reduces exposure of acetaminophen and pentazocine to water and heat.

Dry granulation is a stronger alternative where direct compression produces unacceptable segregation, capping, or tablet-weight variability. Roller compaction can improve blend uniformity without introducing aqueous processing. Wet granulation may provide the best control of powder properties but increases process cost and creates additional stability and validation requirements.

A practical development sequence is:

1. Screen co-processed or engineered diluents for low-dose active uniformity.
2. Compare direct compression with dry granulation.
3. Optimize disintegrant location and concentration.
4. Confirm that lubrication does not slow dissolution.
5. Establish blend uniformity, tablet weight, hardness, friability, disintegration, dissolution, assay, and content-uniformity limits.
6. Conduct stability testing under ICH conditions and evaluate packaging moisture protection.[3]

What formulations are protected by patents?

The commercial product appears to be an established immediate-release tablet rather than a recently developed protected technology. The principal value is therefore in manufacturing execution, regulatory approval, supply reliability, and customer access rather than in broad composition-of-matter exclusivity.

Potentially protectable formulation features include:

• A low-segregation blend for uniform distribution of low-dose pentazocine.
• A moisture-controlled tablet formulation.
• A specific dry-granulation process.
• A taste-masking or film-coating system.
• A tamper-resistant or abuse-deterrent matrix.
• A bilayer or multiparticulate dosage form.
• A formulation that maintains rapid acetaminophen dissolution while controlling pentazocine release.
• A packaging system that reduces degradation or preserves tablet identification.

These features do not automatically create commercially valuable patent claims. For a generic immediate-release tablet, broad claims covering ordinary use of microcrystalline cellulose, crospovidone, povidone, and magnesium stearate would face substantial validity and obviousness pressure. Stronger claims would require a defined composition or process linked to measurable performance, such as improved content uniformity, dissolution, stability, or tamper resistance.

How many patents cover pentazocine hydrochloride and acetaminophen?

The original active-ingredient and combination-product patent position is not a meaningful barrier to an ordinary generic program. The relevant intellectual-property review should separate four categories:

IP category	Commercial relevance
Composition-of-matter patents	Expected to be expired for this legacy combination
Formulation patents	May exist for specific excipient systems, release profiles, or abuse-deterrent designs
Method-of-use patents	May cover a particular pain indication or dosing method, but their practical value depends on labeling and enforceability
Manufacturing patents	Could affect a granulation, coating, or impurity-control process

The FDA Orange Book is the principal U.S. source for patents and regulatory exclusivities tied to approved drug products.[2] A current product-specific Orange Book review should be performed before filing because listed patents can change, and the regulatory significance of a patent depends on its listing, expiration date, and claim scope.

When does pentazocine hydrochloride and acetaminophen lose exclusivity?

The product should be treated as a mature, off-patent combination. FDA approval is therefore more likely to depend on ANDA requirements than on a new-drug exclusivity period.

Exclusivity issue	Assessment
New chemical entity exclusivity	Not applicable to this legacy combination
Five-year NCE period	Expired or unavailable
Three-year clinical-investigation exclusivity	No apparent current basis for the established product
Orphan-drug exclusivity	Not relevant to the ordinary analgesic indication
Pediatric exclusivity	No current protection should be assumed
Patent exclusivity	Requires current Orange Book and USPTO review
Generic pathway	ANDA for a therapeutically equivalent immediate-release product

A generic applicant would typically rely on a Paragraph IV certification if a relevant listed patent remains active and the applicant seeks approval before patent expiration. If no blocking listed patent remains, a Paragraph III certification or a different applicable certification may be used, depending on the Orange Book record and the proposed labeling.

What is the Orange Book status of Talacen?

Talacen is the key reference-product issue for a generic program. The Orange Book should be checked for:

• The listed reference product and strength.
• Whether the product is currently designated a reference standard.
• Approved dosage form and route.
• Therapeutic-equivalence codes.
• Listed patents and pediatric exclusivity.
• Marketing status and any discontinued-product designation.

A discontinued branded product does not necessarily eliminate the regulatory pathway. FDA may identify a reference standard or permit an ANDA strategy based on an approved product record, depending on the current regulatory status. The applicant must align its formulation, labeling, and bioequivalence approach with FDA's active reference-product framework.[2]

Are there Paragraph IV challenges or patent settlements?

No active Paragraph IV challenge or patent settlement is identified in the FDA materials and product records cited here. The commercial probability of a contested patent filing is low if no unexpired Orange Book-listed patent blocks the product.

The more likely regulatory risks are:

• Difficulty identifying an active reference standard.
• Failure to match the reference product's dosage form or release characteristics.
• Deficiencies in controlled-substance security and recordkeeping.
• Inadequate content uniformity for low-dose pentazocine.
• Labeling differences involving opioid warnings or acetaminophen limits.
• Product-specific questions involving discontinued marketing status.

A Paragraph IV strategy would have limited value unless a current listed patent creates an approval delay worth challenging. For a mature analgesic combination, the litigation economics are usually weaker than for a high-revenue, patent-protected product.

What FDA regulatory requirements apply?

An ANDA applicant must establish pharmaceutical equivalence and bioequivalence to the reference product. Pharmaceutical equivalence generally requires the same active ingredients, dosage form, route, strength, and other applicable product characteristics. Bioequivalence normally requires an FDA-acceptable comparative pharmacokinetic study or another approved approach.[4]

The product also requires controlled-substance compliance. Pentazocine manufacturing, storage, distribution, inventory control, and recordkeeping must comply with Drug Enforcement Administration requirements. The manufacturer must control access to the active ingredient and finished product and maintain procedures for diversion prevention.[5]

Acetaminophen creates a separate regulatory concern. FDA has highlighted the risk of severe liver injury from excessive total daily acetaminophen exposure and from simultaneous use of multiple acetaminophen-containing products.[6] A commercial product should use prominent labeling, unit-dose packaging where appropriate, and prescription-channel education to reduce duplicate-therapy risk.

How strong is the patent estate?

The patent estate is likely weak for a conventional immediate-release generic tablet and potentially stronger for differentiated delivery systems.

Product strategy	Patent strength	Commercial attractiveness
Conventional immediate-release tablet	Low	Moderate if manufacturing cost is low
Low-segregation direct-compression formulation	Moderate if performance data support claims	Moderate
Abuse-deterrent formulation	Moderate to high, but development cost is high	Uncertain
Extended-release formulation	Potentially high	Requires new clinical and regulatory work
Taste-masked or orally disintegrating tablet	Moderate	Niche opportunity
Novel packaging and unit-dose presentation	Low to moderate	Useful for institutional channels
505(b)(2) delivery system	Potentially high	Higher regulatory and clinical cost

A formulation patent is strongest when it protects a commercially necessary feature that competitors cannot easily reproduce. A claim limited to routine excipient substitution is less defensible than a claim tied to a defined dissolution profile, impurity level, stability period, or abuse-deterrent performance.

What commercial opportunities exist?

Low-cost generic immediate-release tablet

The clearest opportunity is a standard ANDA product manufactured through direct compression or dry granulation. Competitive advantage would come from:

• Reliable pentazocine supply.
• Low tablet cost.
• High batch yield.
• Strong content-uniformity performance.
• Simple packaging.
• Controlled-substance distribution capability.

The market is unlikely to support many high-cost entrants unless the product has supply shortages, limited current competition, or attractive institutional contracts.

Institutional and specialty distribution

Unit-dose blister packaging could target hospitals, surgical centers, correctional facilities, and other controlled dispensing environments. Packaging does not replace abuse-deterrent technology, but it can improve inventory control, dose accountability, and dispensing efficiency.

Abuse-risk differentiated product

A tamper-resistant product could command a higher price if supported by meaningful abuse-deterrence data and a clear regulatory rationale. The economic case is uncertain because pentazocine/acetaminophen is a relatively mature product and the development cost could exceed the obtainable price premium.

Ex-U.S. opportunity

Pentazocine has established use in some international markets, but regulatory status, opioid scheduling, local pharmacopoeial standards, and demand differ by country. Geographic expansion requires country-specific review of:

• Controlled-substance classification.
• Marketing authorization requirements.
• Acetaminophen labeling limits.
• Local reference products.
• Patent and data-exclusivity status.
• Import and distribution controls.

A multinational strategy should avoid assuming that U.S. ANDA evidence transfers directly to every jurisdiction.

How does pentazocine/acetaminophen compare with competing analgesics?

Product	Main advantage	Main commercial limitation
Pentazocine/acetaminophen	Combines opioid and non-opioid analgesia in one tablet	Controlled-substance obligations and acetaminophen liver-risk warnings
Hydrocodone/acetaminophen	Broad physician familiarity and established demand	Greater competition and tighter opioid scrutiny
Oxycodone/acetaminophen	Strong analgesic efficacy	Higher abuse liability and crowded generic market
Tramadol/acetaminophen	Different pharmacologic profile and broad generic availability	Distinct seizure, serotonin, and opioid-related risks
Acetaminophen alone	Low cost and no controlled-substance handling	Less suitable for severe pain
NSAID combinations	Non-opioid alternative	Gastrointestinal, renal, and cardiovascular limitations

Pentazocine's mixed agonist-antagonist pharmacology may reduce its attractiveness relative to more familiar opioid combinations. Its commercial position depends on clinical niche, prescriber familiarity, supply continuity, and payer reimbursement rather than strong patent protection.

What generic launch risks exist?

The principal launch risks are operational and regulatory:

1. Controlled-substance procurement and quota management.
2. Low-dose pentazocine content uniformity.
3. Acetaminophen overexposure warnings and medication-error risk.
4. Reference-standard and Orange Book positioning.
5. Limited market size and price erosion.
6. Potentially unstable active-ingredient supply.
7. Distribution controls and diversion monitoring.
8. Product liability exposure associated with opioid use.
9. Difficulty differentiating a conventional tablet.
10. Low return on investment if several ANDA competitors enter simultaneously.

A formulation program should prioritize reproducibility and cost before pursuing patent-heavy delivery systems. The strongest near-term business case is a compliant, low-cost immediate-release generic with dependable supply and institutional packaging.

Key Takeaways

• Pentazocine hydrochloride/acetaminophen is a mature immediate-release analgesic combination centered on Talacen.
• The standard strength is 12.5 mg pentazocine hydrochloride and 650 mg acetaminophen per tablet.
• The conventional product is best approached through an ANDA strategy, subject to current FDA reference-product and Orange Book records.
• Direct compression or dry granulation is likely to provide the best balance of cost, stability, and manufacturing simplicity.
• Low-dose pentazocine creates a meaningful content-uniformity and segregation risk.
• Broad formulation patent opportunities are limited, but defined low-segregation, stability, abuse-deterrent, or delivery-system claims may have value.
• The main barriers are controlled-substance compliance, acetaminophen safety, supply reliability, and market economics.
• No active Paragraph IV challenge or settlement is identified in the FDA materials cited.
• The strongest commercial opportunity is a low-cost generic with robust quality control and controlled-distribution capability.

FAQs

Is pentazocine hydrochloride and acetaminophen still commercially viable?

Yes, but primarily as a focused generic or institutional product. The opportunity depends on market size, competitor count, reference-product availability, and reliable controlled-substance supply.

Can pentazocine/acetaminophen be developed as an abuse-deterrent product?

Yes, but a meaningful abuse-deterrent claim would require a defined technology, comparative testing, and FDA acceptance. The development cost may be disproportionate to the market opportunity.

Which excipient is most important for pentazocine content uniformity?

The most important factor is the combined powder-engineering system, including diluent particle-size distribution, blend segregation control, and the process used to distribute the low-dose pentazocine component. No single excipient guarantees uniformity.

Is a 505(b)(2) application preferable to an ANDA?

An ANDA is generally more efficient for a conventional immediate-release tablet. A 505(b)(2) pathway becomes more relevant for a new dosage form, extended-release system, abuse-deterrent technology, or other clinically meaningful modification.

Does acetaminophen create a separate patent opportunity?

Acetaminophen itself is an old active ingredient. Patent value would more likely arise from a defined combination formulation, release profile, packaging system, or manufacturing process than from acetaminophen as an ingredient.

References

1. U.S. Food and Drug Administration. (n.d.). Talacen prescribing information: Pentazocine hydrochloride and acetaminophen tablets. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
4. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products.
5. U.S. Drug Enforcement Administration. (n.d.). Controlled substances act and regulatory requirements for manufacturers and distributors.
6. U.S. Food and Drug Administration. (2011). Questions and answers about FDA's actions regarding prescription combination products containing acetaminophen.